Shi-Jun Li

Shi-Jun Li

Auto-generated profile, based on publicly available information

Shi-Jun Li

College of Medical Laboratory, Dalian Medical University, Dalian, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
XZXu Zhai
Xu Zhai
SLShi-Jun Li
Shi-Jun Li
This study aimed to evaluate the methylation of RASSF1A and CDH13 gene promoter regions as a marker for monitoring chemotherapeutic efficacy with personalized medicine for patients with NSCLC, in the hope of providing a new direction for NSCLC individualized chemotherapy. 42 NSCLC patients and 40 healthy controls were included. Patient blood samples were collected in the whole process of chemotherapy. Methylation of RASSF1A and CDH13 gene promoter regions was detected by the methylation specific polymerase chain reaction (MSP). The rate of RASSF1A and CDH13 gene methylation in 42 cases of NSCLC patients was significantly higher than in 40 healthy controls (52.4% to 0.0%, 54.8% to 0.0%, p0.05). With chemotherapy, RASSF1A and CDH13 promoter region methylation rate in 42 cases of patients showed a declining trend. The methylation level of RASSF1A and CDH13 gene promoter region can reflect drug sensitivity of tumors to individualized treatment.

23 April 2012 in Oncology Reports
Verified
Journal Article
Open access
PDF file
SLShijun Li
Shijun Li
GSGuangxia Shi
Guangxia Shi
HYHong Yuan
Hong Yuan
TZTao Zhou
Tao Zhou
QZQiuping Zhang
Qiuping Zhang
XWXiaoyan Wang
Xiaoyan Wang
The p53 protein is one of the best-known tumor suppressors. Recently discovered ASPP1 and ASPP2 are specific activators and iASPP is an inhibitor of p53. In the present study, we found that of 37 NSCLC patients, p53 alterations were detected in 20 tumors (54.1%), the mRNA expression of ASPP1 and ASPP2 was frequently dowregulated in tumor tissues, and this decreased significantly in samples expressing wild-type p53. The expression of ASPP1 and ASPP2 was downregulated and that of iASPP was upregulated in two NSCLC cell lines (the NCI-H157 cell line with altered p53 and the A549 cell line with wild-type p53). The NCI-H157 cell with higher ASPP1 and ASPP2 levels was more sensitive to cisplatin than the A549 cells with lower ASPP1 and ASPP2 levels. Downregulation of iASPP by siRNA stimulated apoptosis through p53 in two NSCLC cell lines. These findings provide new insights into the molecular mechanisms of action of the ASPP family in NSCLC and may have potent therapeutic applications.

8 September 2013 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
DMDuan Mengxi
Duan Mengxi
WQWang Qian
Wang Qian
WNWang Nan
Wang Nan
XXXiaoGuang Xiao
XiaoGuang Xiao
LSLi Shijun
Li Shijun
Background: Ras association domain family 1A gene (RASSFlA) is a candidate suppressor gene, Lack of RASSF1A expression was found in lung cancer. High DNA methylation at the promoter region is the main reason for inactivating RASSF1A transcription. Methods: In this study, we examined RASSF1A’s methylation status and its mRNA expression level between non-small cell lung cancer cell line A549 and anti-Cisplatin cell strain A549DDP, Furthermore, methylation of A549DDP was reversed by treatment of 5-Aza-2′ - deoxycytidine (5-Aza-cdR),a DNA methyltransferase inhibitor. Results: We found that RASSF1A’s methylation status and its mRNA expression were obvious differences between A549 and A549DDP. 5-Aza-CdR treatment remarkablly reduced cell vability of A549DDP. Moreover, 5-Aza-CdR treatment induced A549DDP cell apoptosis in a dose dependent manner with declining cell percentage in S and G2/M stage, and increasing proportion in G0/G1 stage. Cell motility was blocked in G0/G1 stage. All of A549DDP cells showed unmethylated expression, its high methylation status was reversed in a dose-dependent manner within a certain range. Conclusions: The abnormal gene methylation status of RASSF1A is a molecular biomarker in lung cancer diagnosis, treatment and prognosis.

1 August 2017 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YZYilin Zhao
Yilin Zhao
SLShijun Li
Shijun Li
LHLiu Hui
Liu Hui
This study aimed to establish a model that estimates the survival advantage at the molecular level based on telomere length and serum biomarkers of aging, to explore clinical significance. The study consisted of 100 healthy subjects and 40 type 2 diabetes mellitus patients, 20–90 years of age. Saliva telomere relative length (LnTL) was measured by the quantitative real-time polymerase chain reaction and the serum biochemical parameters, including albumin (ALB), total proteins, total cholesterol, triglycerides, and some enzyme parameters were detected by a biochemical analyzer. The Z values were transformed from mean values and standard deviations to estimate the survival advantage. A normal reference range (95% confidence interval) was set to the comprehensive advantage of the Z values (Zs) to evaluate the comprehensive survival advantage. The Z values of serum ALB and saliva LnTL could be used to estimate the survival advantage, and effectively distinguish between the aging and nonaging individuals. The Zs was greater than 1.64 in the normal reference range, and type 2 diabetes mellitus patients had lower survival advantages compared to those of the control group (p < 0.05). Our two-dimensional model system using ALB and LnTL was valid and may have potential applications for evaluating the aging status at the molecular level, and for the observation of disease characteristics.

1 October 2013
Verified
Journal Article
Closed access
MDMeng-Xi Duan
Meng-Xi Duan
CBCong-Xi Bi
Cong-Xi Bi
HCHui Chen
Hui Chen
NWNan Wang
Nan Wang
SLShi-Jun Li
Shi-Jun Li
HYHong Yuan
Hong Yuan

1 February 2009
Verified
Journal Article
Closed access
YJYan-Mei Jiang
Yan-Mei Jiang
HYHong Yuan
Hong Yuan
XLXin-Yuan Liu
Xin-Yuan Liu
BWBin Wang
Bin Wang
SLShi-Jun Li
Shi-Jun Li
NWNan Wang
Nan Wang